Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: Correlation with outcome of pegylated IFN-α and ribavirin treatment

Journal of Immunology

Volumn 183, Issue 10, 2009, Pages 6612-6618

  Gonzalez, Veronica D ^a   Falconer, Karolin ^a   Björkström, Niklas K ^a   Blom, Kim G ^a   Weiland, Ola ^a   Ljunggren, Hans Gustaf ^a   Alaeus, Annette ^a   Sandberg, Johan K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PEGINTERFERON ALPHA2A; PERFORIN; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL EXPANSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; INNATE IMMUNITY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD56; ANTIGENS, CD57; ANTIVIRAL AGENTS; CELL DEGRANULATION; CHEMOKINE CCL4; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERFORIN; RECEPTORS, NATURAL KILLER CELL; RIBAVIRIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77649232232     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901437     Document Type: Article

References (40)

1. Lodoen, M. B., and L. L. Lanier. 2006. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol. 18: 391-398.
2. Fauci, A. S., D. Mavilio, and S. Kottilil. 2005. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5: 835-843.
3. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5: 215-229.
4. Caligiuri, M. A. 2008. Human natural killer cells. Blood 112: 461-469.
5. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
6. Chan, A., D. L. Hong, A. Atzberger, S. Kollnberger, A. D. Filer, C. D. Buckley, A. McMichael, T. Enver, and P. Bowness. 2007. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J. Immunol. 179: 89-94.
7. - cells with low lytic activity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10: 331-340.
8. Alter, G., N. Teigen, B. T. Davis, M. M. Addo, T. J. Suscovich, M. T. Waring, H. Streeck, M. N. Johnston, K. D. Staller, M. T. Zaman, et al. 2005. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106: 3366-3369.
9. + natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. USA 102: 2886-2891.
10. Eller, M. A., L. A. Eller, B. J. Ouma, D. Thelian, V. G. Gonzalez, D. Guwatudde, F. E. McCutchan, M. A. Marovich, N. L. Michael, M. S. de Souza, et al. 2009. Elevated NK cell activity despite altered functional and phenotypic profile in ugandans with HIV-1 clade A or clade D infection. J. Acquir. Immune Defic. Syndr. 51: 380-389.
11. - NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNα and ribavirin. Clin. Immunol. 128: 46-56.
12. Notas, G., T. Kisseleva, and D. Brenner. 2009. NK and NKT cells in liver injury and fibrosis. Clin. Immunol. 130: 16-26.
13. Khakoo, S. I., C. L. Thio, M. P. Martin, C. R. Brooks, X. Gao, J. Astemborski, J. Cheng, J. J. Goedert, D. Vlahov, M. Hilgartner, et al. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872-874.
14. Wang, S. H., C. X. Huang, L. Ye, X. Wang, L. Song, Y. J. Wang, H. Liang, X. Y. Huang, and W. Z. Ho. 2008. Natural killer cells suppress full cycle HCV infection of human hepatocytes. J. Viral Hepat. 15: 855-864.
15. Meier, U. C., R. E. Owen, E. Taylor, A. Worth, N. Naoumov, C. Willberg, K. Tang, P. Newton, P. Pellegrino, I. Williams, et al. 2005. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J. Virol. 79: 12365-12374.
16. De Maria, A., M. Fogli, S. Mazza, M. Basso, A. Picciotto, P. Costa, S. Congia, M. C. Mingari, and L. Moretta. 2007. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur. J. Immunol. 37: 445-455.
17. Nattermann, J., G. Feldmann, G. Ahlenstiel, B. Langhans, T. Sauerbruch, and U. Spengler. 2006. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55: 869-877.
18. Golden-Mason, L., L. Madrigal-Estebas, E. McGrath, M. J. Conroy, E. J. Ryan, J. E. Hegarty, C. O'Farrelly, and D. G. Doherty. 2008. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57: 1121-1128.
19. Feld, J. J., and J. H. Hoofnagle. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
20. Backus, L. I., D. B. Boothroyd, B. R. Phillips, and L. A. Mole. 2007. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46: 37-47.
21. El-Shamy, A., M. Nagano-Fujii, N. Sasase, S. Imoto, S. R. Kim, and H. Hotta. 2008. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48: 38-47.
22. Loustaud-Ratti, V., S. Alain, A. Rousseau, I. F. Hubert, F. L. Sauvage, P. Marquet, F. Denis, F. Lunel, P. Cales, A. Lefebvre, et al. 2008. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 47: 1453-1461.
23. Ge, D., J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, T. J. Urban, E. L. Heinzen, P. Qiu, A. H. Bertelsen, A. J. Muir, M. Sulkowski, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
24. Sarasin-Filipowicz, M., J. Krol, I. Markiewicz, M. H. Heim, and W. Filipowicz. 2009. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15: 31-33.
25. Butera, D., S. Marukian, A. E. Iwamaye, E. Hembrador, T. J. Chambers, A. M. Di Bisceglie, E. D. Charles, A. H. Talal, I. M. Jacobson, C. M. Rice, and L. B. Dustin. 2005. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 106: 1175-1182.
26. Diago, M., G. Castellano, J. Garcia-Samaniego, C. Perez, I. Fernandez, M. Romero, O. L. Iacono, and C. Garcia-Monzon. 2006. Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 55: 374-379.
27. Romero, A. I., M. Lagging, J. Westin, A. P. Dhillon, L. B. Dustin, J. M. Pawlotsky, A. U. Neumann, C. Ferrari, G. Missale, B. L. Haagmans, et al. 2006. Interferon (IFN)-γ-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic hepatitis C virus infection. J. Infect. Dis. 194: 895-903.
28. Falconer, K., J. K. Sandberg, O. Reichard, and A. Alaeus. 2009. HCV/HIV coinfection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment. Scand. J. Infect. Dis. Epub ahead of print.
29. Gonzalez, V. D., N. K. Bjorkstrom, K. J. Malmberg, M. Moll, C. Kuylenstierna, J. Michaelsson, H. G. Ljunggren, and J. K. Sandberg. 2008. Application of ninecolor flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets. J. Immunol. Methods 330: 64-74.
30. Schakel, K., R. Kannagi, B. Kniep, Y. Goto, C. Mitsuoka, J. Zwirner, A. Soruri, M. von Kietzell, and E. Rieber. 2002. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 17: 289-301.
31. + T lymphocytes. J. Immunol. 167: 181-187.
32. + T cells. Blood 107: 4781-4789.
33. Ishii, S., and M. J. Koziel. 2008. Immune responses during acute and chronic infection with hepatitis C virus. Clin. Immunol. 128: 133-147.
34. Goulding, C., R. McManus, A. Murphy, G. MacDonald, S. Barrett, J. Crowe, J. Hegarty, S. McKiernan, and D. Kelleher. 2005. The CCR5-δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 54: 1157-1161.
35. Hellier, S., A. J. Frodsham, B. J. Hennig, P. Klenerman, S. Knapp, P. Ramaley, J. Satsangi, M. Wright, L. Zhang, H. C. Thomas, et al. 2003. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38: 1468-1476.
36. Mavilio, D., J. Benjamin, M. Daucher, G. Lombardo, S. Kottilil, M. A. Planta, E. Marcenaro, C. Bottino, L. Moretta, A. Moretta, and A. S. Fauci. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. USA 100: 15011-15016.
37. Chehimi, J., L. Azzoni, M. Farabaugh, S. A. Creer, C. Tomescu, A. Hancock, A. Mackiewicz, L. D'Alessandro, S. Ghanekar, A. S. Foulkes, et al. 2007. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J. Immunol. 179: 2642-2650.
38. Barker, E., J. Martinson, C. Brooks, A. Landay, and S. Deeks. 2007. Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS 21: 2363-2365.
39. + T cells. Eur. J. Immunol. 38: 995-1000.
40. + T cells. Blood 101: 2711-2720.